Literature and guidelines often cite cardiotoxicity rates of 15-20% associated with trastuzumab in patients with HER2-positive breast cancer, primarily on the basis of early trials. A closer look at ...
July 26, 2006 —The cardiotoxic effects related to the leukemia drug imatinib ( Gleevec in the United States, Glivec elsewhere; Novartis) "is a big surprise," says the researcher heading the team that ...
Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human ...
Scholastic Achievements of Childhood Leukemia Patients: A Nationwide, Register-Based Study The design and efficacy of the major adjuvant trastuzumab trials was assessed, including the National ...
Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have identified the mechanisms through which anthracyclines, a widely used class of anticancer drugs, damage the hearts of ...
A new research perspective titled "Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification" has been published in Oncotarget. In ...
In patients with gastrointestinal cancers treated with fluoropyrimidine-based chemotherapy agents, better overall survival at 1 year offsets a small increase in their risk of CV events, new data ...
BARCELONA — Cardiovascular disease risk factors, as well as established disease, in patients undergoing cancer therapy can be safely managed to minimize cancer therapy-related cardiovascular toxicity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results